Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,436,965 papers from all fields of science
Search
Sign In
Create Free Account
fenproporex
Known as:
Fenorex
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
5 relations
Broader (1)
Amphetamines
Narrower (3)
Fenproporex hydrochloride
Ifa Diety
Perphoxene
Fenproporex:MRat:24H:Urine:Qn
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Safety and efficacy of fenproporex for obesity treatment: a systematic review
F. Paumgartten
,
Sabrina Schaaf Teixeira Costa Pereira
,
Ana Cecilia Amado Xavier de Oliveira
Revista de Saúde Pública
2016
Corpus ID: 18907253
ABSTRACT OBJECTIVE To evaluate clinical evidence on the safety and efficacy of fenproporex for treating obesity. METHODS MEDLINE…
Expand
2013
2013
Screening of pharmacologic adulterant classes in herbal formulations using voltammetry of microparticles.
A. Doménech‐Carbó
,
M. Martini
,
L. M. de Carvalho
,
C. Viana
,
M. Doménech‐Carbó
,
Miguel F. Silva
Journal of Pharmaceutical and Biomedical Analysis
2013
Corpus ID: 40578898
2013
2013
Fenproporex Increases Locomotor Activity and Alters Energy Metabolism, and Mood Stabilizers Reverse These Changes: a Proposal for a New Animal Model of Mania
G. Rezin
,
C. B. Furlanetto
,
+9 authors
E. Streck
Molecular Neurobiology
2013
Corpus ID: 15024872
Fenproporex (Fen) is converted in vivo into amphetamine, which is used to induce mania-like behaviors in animals. In the present…
Expand
2010
2010
An evaluation of the genotoxic and cytotoxic effects of the anti-obesity drugs sibutramine and fenproporex
Cristiano José da Silva
,
José Ernesto dos Santos
,
Catarina Satie Takahashi
Human and Experimental Toxicology
2010
Corpus ID: 22772713
Anti-obesity medications deserve special considerations at the present time due to an increasing number of overweight and obese…
Expand
2001
2001
A contemporaneous finding of fenproporex in a polydrug suicide.
Ronald R. Bell
,
Susan B. Crookham
,
William A. Dunn
,
Kirk M. Grates
,
Tina M. Reiber
Journal of Analytical Toxicology
2001
Corpus ID: 25352159
Fenproporex is a sympathomimetic agent with a pharmacological profile similar to that of amphetamine. It is available in many…
Expand
1999
1999
Amphetamine and fenproporex levels following multidose administration of fenproporex.
J. Cody
,
S. Valtier
,
Stedra L. Stillman
Journal of Analytical Toxicology
1999
Corpus ID: 43032322
Drugs that are metabolized to amphetamine or methamphetamine are potentially of significant concern in the interpretation of…
Expand
1996
1996
Detection of amphetamine following administration of fenproporex.
J. Cody
,
S. Valtier
Journal of Analytical Toxicology
1996
Corpus ID: 18699954
Drugs that are metabolized to amphetamine or methamphetamine are potentially significant concerns in the interpretation of…
Expand
1996
1996
A comparative study of the anorectic and behavioral effects of fenproporex on male and female rats.
Rita Mattei
,
Elisaldo Araújo Carlini
Brazilian journal of medical and biological…
1996
Corpus ID: 32549991
The anorectic and behavioral effects of fenproporex (Fenp, 10 mg/kg, ip) and methamphetamine (Met, 2.5 mg/kg, ip), a prototypical…
Expand
1996
1996
Consumption of anorexigenic amphetamine‐like drugs (diethylpropion, fenproporex and mazindol) and of d,1‐fenfluramine in Brazil during the years of 1988 and 1989
S. Nappo
Pharmacoepidemiology and Drug Safety
1996
Corpus ID: 10877003
Brazilian consumption of psychotimulant anorexigenic drugs — diethylpropion, fenproporex, and mazindol — and of 3,1‐fenfluramine…
Expand
1983
1983
Amphetamine in rat brain after intraperitoneal injection of N-alkylated analogues
A. Nazarali
,
G. Baker
,
R. T. Coutts
,
F. Pasutto
Progress in Neuro-psychopharmacology and…
1983
Corpus ID: 35531794
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE